THE MTT CELL VIABILITY ASSAY FOR CYTOTOXICITY TESTING IN MULTIDRUG-RESISTANT HUMAN LEUKEMIC-CELLS

被引:164
作者
MARKS, DC
BELOV, L
DAVEY, MW
DAVEY, RA
KIDMAN, AD
机构
[1] UNIV TECHNOL SYDNEY,SCH BIOL & BIOMED SCI,NEUROBIOL UNIT,WESTBOURNE ST,GORE HILL,NSW 2065,AUSTRALIA
[2] ROYAL N SHORE HOSP,DEPT CLIN ONCOL,ST LEONARDS,NSW 2065,AUSTRALIA
关键词
MTT; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; CELL VIABILITY ASSAY; CYTOTOXICITY ASSAY; CCRF-CEM; K562 LEUKEMIC CELLS;
D O I
10.1016/0145-2126(92)90114-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The MTT cell viability assay is widely used in determining drug sensitivity profiles for patients with hematological malignancies and in.primary screening of potential chemotherapeutic drugs. Because the multidrug resistance (MDR) phenotype is associated with these malignancies, and since many vital dyes are effluxed from MDR expressing cells, we have investigated whether the MDR phenotype interferes with the MTT assay. In CCRF-CEM and K562 human leukemic cell lines and drug-resistant sub-lines developed from them, comparison of the MTT assay with other cell viability assays showed significant variation in IC50 concentrations, although the resistance relative to the sensitive parent cell was correlated. Inclusion of verapamil, an inhibitor of drug efflux activity, had no effect on the MTT assay.
引用
收藏
页码:1165 / 1173
页数:9
相关论文
共 21 条
[1]  
ALLEY MC, 1988, CANCER RES, V48, P589
[2]  
BECK WT, 1979, CANCER RES, V39, P2070
[3]   RETENTION OF VITAL DYES CORRELATES INVERSELY WITH THE MULTIDRUG-RESISTANT PHENOTYPE OF ADRIAMYCIN-SELECTED MURINE FIBROSARCOMA VARIANTS [J].
BUCANA, CD ;
GIAVAZZI, R ;
NAYAR, R ;
OBRIAN, CA ;
SEID, C ;
EARNEST, LE ;
FAN, D .
EXPERIMENTAL CELL RESEARCH, 1990, 190 (01) :69-75
[4]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[5]  
DAVEY R, 1983, BIOCHEM INT, V6, P643
[6]   THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE [J].
ENDICOTT, JA ;
LING, V .
ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 :137-171
[7]  
FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO
[8]  
2-J
[9]   EVIDENCE OF A SPECIFIC COMPLEX BETWEEN ADRIAMYCIN AND NEGATIVELY-CHARGED PHOSPHOLIPIDS [J].
GOORMAGHTIGH, E ;
CHATELAIN, P ;
CASPERS, J ;
RUYSSCHAERT, JM .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 597 (01) :1-14
[10]  
HABER M, 1989, CANCER RES, V49, P5281